GLP-1 Medication Information
Online intake — Additional evaluation may be required
This section identifies GLP-1 medications and the information considered during a prescription review. An intake does not guarantee a prescription.
What Is GLP-1 Medication?
GLP-1 stands for glucagon-like peptide-1. Semaglutide and liraglutide are GLP-1 receptor agonists; tirzepatide is classified as a GIP and GLP-1 receptor agonist. The products have different formulations and labeled indications.
Who May Be a Candidate
Review includes height, weight, diagnoses, current medicines, allergies, pregnancy plans, and prior medication use. Eligibility depends on the specific product and the clinician's assessment.
How OakMD Works
OakMD is a telemedicine platform connecting eligible adults with licensed providers. If you're interested in GLP-1 Medication, the process begins with a brief online intake form. A licensed provider will review your health history, symptoms, and goals — and determine if treatment is appropriate for you.
A prescription is not guaranteed. Additional records, testing, a live visit, or in-person care may be required before a prescribing decision.
Common Questions
Are all GLP-1 products administered the same way?
No. Formulation, route, schedule, and instructions differ by product. Follow the prescription and product label rather than instructions for another brand or preparation.
What warnings require discussion before a prescription?
Semaglutide, tirzepatide, and liraglutide products carry a boxed warning about thyroid C-cell tumors observed in rodents; the relevance to humans is unknown. They are contraindicated with a personal or family history of medullary thyroid carcinoma (MTC), multiple endocrine neoplasia syndrome type 2 (MEN2), or serious hypersensitivity to the prescribed product.
What other risks should I review with a clinician?
Risks include nausea, vomiting, diarrhea, constipation, severe gastrointestinal reactions, pancreatitis, gallbladder disease, kidney injury related to dehydration, and serious allergic reactions. Hypoglycemia risk increases with insulin or sulfonylureas. Discuss gastroparesis, diabetic eye disease, pregnancy plans, and all medicines. These products are not recommended with severe gastroparesis. Tell procedural teams about use before anesthesia or deep sedation because pulmonary aspiration has been reported. Seek urgent care for severe persistent abdominal pain, breathing difficulty, or swelling of the face or throat.
How do brand-name and compounded products differ?
FDA approval applies to the specific approved product and its labeling, not to every preparation containing that ingredient. Compounded drugs are not FDA-approved; the FDA does not review them for safety, effectiveness, or quality before marketing. A compounded preparation is not an FDA-approved generic of a brand-name product.
Ready to Get Started?
Complete a brief online intake. A licensed provider will review your information and determine if treatment is appropriate for you.
The information provided through the OakMD® website, assessments, product pages, checkout flows, communications, and related services is for general informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
Medical Disclaimer: The information provided through the OakMD® website, assessments, product pages, checkout flows, communications, and related services is for general informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
Prescription treatment, if any, is provided only after review by a US-licensed provider and only if clinically appropriate. Read the full Medical Disclaimer.